In the MSKCC Phase 1 trial, autologous CD19-targeted CAR T cells expressing the second-generation CAR (19-28z) were evaluated for their safety and persistence in treating relapsed or chemotherapy refractory CLL and B-ALL. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.